Article Information
History
- October 11, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ashley L. O’Donoghue, PhD1,*,
- Alyse Reichheld, BA1,2,
- Timothy S. Anderson, MD, MAS1,3,
- Chloe A. Zera, MD4,
- Tenzin Dechen, MPH1 and
- Jennifer P. Stevens, MD MS1,5
- 1Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, MA
- 2Tufts University School of Medicine, Boston, MA
- 3Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, MA
- 4Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA
- 5Division for Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
- ↵*Corresponding author:
Ashley L. O’Donoghue, PhD, Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215 email: aodonogh{at}bidmc.harvard.edu
Posted October 11, 2021.
Decline in prenatal buprenorphine/naloxone fills during the COVID-19 pandemic in the United States
